Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | CML: care versus cure

Francois-Xavier Mahon • 26 Nov 2021
ASH 2021
Chronic Myeloid Leukemia Leukemia

Francois-Xavier Mahon, MD, PhD, University of Bordeaux, Bordeaux, France, shares his thoughts on the likelihood of achieving cure in chronic myeloid leukemia (CML). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Francois-Xavier Mahon

Recommendations for treatment discontinuation in CML
2:18
Recommendations for treatment discontinuation in CML
Francois-Xavier Mahon • 22 Oct 2022
Design & aims of the EURO-SKI trial in CML
0:54
Design & aims of the EURO-SKI trial in CML
Francois-Xavier Mahon • 22 Oct 2022
Key challenges in CML: QoL, managing CML in resource-challenged countries & achieving a cure
1:24
Key challenges in CML: QoL, managing CML in resource-challenged countries & achieving a cure
Francois-Xavier Mahon • 22 Oct 2022
Feasibility of treatment cessation in patients with CML with atypical BCR-ABL fusion transcripts
1:05
Feasibility of treatment cessation in patients with CML with atypical BCR-ABL fusion transcripts
Francois-Xavier Mahon • 26 Nov 2021

Related Videos

Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
4:56
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer • 16 Oct 2026
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
The content of VJHemOnc is intended for healthcare professionals